Expert Review of Clinical Pharmacology 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.JAK inhibitors in vitiligo: what they hit and what they miss - an immunopathogenesis based exposition of existing evidence
Expert Rev Clin Pharmacol. 2023 Nov 20:1-7. doi: 10.1080/17512433.2023.2285011. Online ahead of print.ABSTRACTINTRODUCTION: Vitiligo is an autoimmune disorder which presents as depigmented macules due to selective loss of melanocytes. Heightened expression of Janus Kinase Signal transducers and activators of transcription (JAK STAT) pathway, which mediate cytokines action, suggest that targeting this signaling pathway may be an effective option.AREAS COVERED: A PubMed search was carried out with the broad key words 'JAK,' 'vitiligo' from 2016 to 2023. We also analyzed papers where tissue-based JAK expression was studied, w...
Source: Expert Review of Clinical Pharmacology - November 20, 2023 Category: Drugs & Pharmacology Authors: Kabir Sardana Aishwarya Muddebihal Ananta Khurana Source Type: research
JAK inhibitors in vitiligo: what they hit and what they miss - an immunopathogenesis based exposition of existing evidence
Expert Rev Clin Pharmacol. 2023 Nov 20. doi: 10.1080/17512433.2023.2285011. Online ahead of print.ABSTRACTINTRODUCTION: Vitiligo is an autoimmune disorder which presents as depigmented macules due to selective loss of melanocytes. Heightened expression of Janus Kinase Signal transducers and activators of transcription (JAK STAT) pathway which mediate cytokines action, suggests that targeting this signaling pathway may be an effective option.AREAS COVERED: A PubMed search was carried out with the broad key words 'JAK,' 'vitiligo' from 2016 to 2023. We have also analyzed papers where tissue-based JAK expression was studied, ...
Source: Expert Review of Clinical Pharmacology - November 20, 2023 Category: Drugs & Pharmacology Authors: Kabir Sardana Aishwarya Muddebihal Ananta Khurana Source Type: research
Determinants of adherence to treatment in patients with ophthalmic conditions
CONCLUSION: We identified as determinants for encouraging good ophthalmic adherence the adverse events presented, duration of the study, female sex, and older age; other determinants such as medical condition, protocol treatment, type of treatment and disease are all risk factors for adherence. Improvements in ophthalmic adherence may be achieved by focused attention to young male patients with chronic degenerative diseases such as glaucoma or ocular hypertension (especially those who need combination therapy) and developing medications with reduced side effects.PMID:37978952 | DOI:10.1080/17512433.2023.2279740 (Source: Ex...
Source: Expert Review of Clinical Pharmacology - November 18, 2023 Category: Drugs & Pharmacology Authors: Patricia Mu ñoz-Villegas Humberto Mart ínez-Bautista Oscar Olvera-Monta ño Source Type: research
Pharmacokinetics and pharmacodynamics of Hedgehog pathway inhibitors used in the treatment of advanced or treatment-refractory basal cell carcinoma
Expert Rev Clin Pharmacol. 2023 Nov 17. doi: 10.1080/17512433.2023.2285849. Online ahead of print.ABSTRACTINTRODUCTION: Sonidegib and vismodegib are currently the only US Food and Drug Administration and European Medicines Agency-approved small-molecule Hedgehog pathway inhibitors (HHIs), for treating adults with advanced or refractory basal cell carcinoma (BCC) that is not amenable to conventional surgery or radiotherapy. At this time, there are no head-to-head clinical trials comparing these two HHIs for efficacy and safety to assist clinicians with determining which HHI may be best suited for their patients.AREAS COVERE...
Source: Expert Review of Clinical Pharmacology - November 17, 2023 Category: Drugs & Pharmacology Authors: John T Lear Linda M Morris Dylan B Ness Lionel D Lewis Source Type: research
Stimulant and hallucinogenic novel psychoactive substances; an update
Expert Rev Clin Pharmacol. 2023 Nov 15:1-15. doi: 10.1080/17512433.2023.2279192. Online ahead of print.ABSTRACTINTRODUCTION: The renewed interest in considering a range of stimulants, psychedelics and dissociatives as therapeutics emphasizes the need to draft an updated overview of these drugs' clinical and pharmacological issues.AREAS COVERED: The focus here was on: stimulants (e.g. amphetamines, methamphetamine, and pseudoephedrine; phenethylamines; synthetic cathinones; benzofurans; piperazines; aminoindanes; aminorex derivatives; phenmetrazine derivatives; phenidates); classical (e.g. ergolines; tryptamines; psychedeli...
Source: Expert Review of Clinical Pharmacology - November 16, 2023 Category: Drugs & Pharmacology Authors: F Schifano A Vento N Scherbaum A Guirguis Source Type: research
The effectiveness of cerebrolysin, a multi-modal neurotrophic factor, for treatment of post-covid-19 persistent olfactory, gustatory and trigeminal chemosensory dysfunctions: a randomized clinical trial
CONCLUSIONS: Cerebrolysin had fast, promising and constant effect, with cure rate of > 60%. This might be due to its ability to initiate and enhance neuronal regeneration and reorganization of sensory epithelia.PMID:37950370 | DOI:10.1080/17512433.2023.2282715 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - November 11, 2023 Category: Drugs & Pharmacology Authors: Sherifa Ahmed Hamed Mohamed Azzam Abdel-Razek Ahmed Source Type: research
